COVID-19, a highly infective disease caused by a newly identified coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously 2019-nCoV), is spreading around the world [@bib0005]. Increasing evidence has confirmed the human-to-human transmission. A special group of COVID-19 patients is comorbid with chronic kidney disease (CKD) [@bib0010]. In patients with CKD, innate and adaptive immune function impairment would result in increased susceptibility to bacterial and viral infections. Therefore, SARS-CoV-2 infection of these dialysis patients has attracted our attention.

High risk {#sec0005}
=========

As reported in our previous study, 41.30% of COVID-19 patients were likely infected in hospital. Most renal failure patients were immunocompromised due to uremia and needed routine dialysis in hospital two to three times per week. Therefore, renal failure patients should be more susceptible to SARS-CoV-2 than the normal population. We noticed that, as chest computed tomography scans show, approximately 20--30% of dialysis patients were diagnosed with suspected infection in multiple dialysis centers in the early period of COVID-19 outbreak. Intriguingly, most of these suspected cases have no obvious clinical symptoms, including fever, fatigue, and dry cough. However, these asymptomatic patients may be a potential source of infection, transmitting the virus to healthcare providers, their family members, and other patients. Therefore, SARS-CoV-2 infection in dialysis patients should be taken more seriously due to a high risk of asymptomatic transmission.

Diagnosis {#sec0010}
=========

Healthcare-associated pneumonia is a common infectious problem encountered in hemodialysis patients [@bib0015], [@bib0020]. Moreover, many dialysis patients suffer concurrently from pulmonary edema, which may mimic pneumonia, in terms of both presenting with an abnormal chest radiograph and producing a similar clinical symptom. Nucleic acid test could provide a valuable support, but the sensitivity of the current nucleic acid tests needs to be improved. Given all of the above, the precise diagnosis of COVID-19 infection is more difficult in dialysis patients than in the normal population.

Treatment {#sec0015}
=========

Another concern is the pharmacokinetics in these renal failure patients. Many antiviral drugs are eliminated by hepatic metabolism and renal excretion. There are few studies on the pharmacokinetics of antiviral drugs in patients with renal dysfunction. In addition, hemodialysis could take away some drugs and reduce their concentration in the blood. Taken together, an adjusted or even supplemental dose of those antiviral drugs should be administered.

In addition, a previous study has indicated that renal dysfunction in patients with pneumonia is associated with a risk of severe infection [@bib0025]. A higher mortality rate should be observed in renal failure patients infected with the coronavirus. Indeed, SARS-CoV-2 infection can induce acute renal injury, and this might superimpose the patient with an underlying renal problem [@bib0010].

In conclusion, SARS-CoV-2 infection should be monitored intensively for dialysis patients due to immunorepression, difficulty in diagnosis, and additional concern regarding the use of antiviral drugs. Our report should prompt experts and medical workers to pay special attention to the SARS-CoV-2 infection of dialysis patients.
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